Skip Navigation

JNCI Monographs 2005 2005(34):12-17; doi:10.1093/jncimonographs/lgi003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Howell, S. J.
Right arrow Articles by Shalet, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howell, S. J.
Right arrow Articles by Shalet, S. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

2005 © Oxford University Press

Spermatogenesis After Cancer Treatment: Damage and Recovery

S. J. Howell, S. M. Shalet

Affiliation of authors: Department of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, United Kingdom

Correspondence to: Professor S. M. Shalet, Department of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, UK M20 4BX (e-mail: stephen.m.shalet{at}man.ac.uk).

Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men, and alkylating agents are the most common agents implicated. The vast majority of men receiving procarbazine-containing regimens for the treatment of lymphomas are rendered permanently infertile, whereas treatment with doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine, and dacarbazine appears to have a significant advantage, with a return to normal fertility in the vast majority of patients. Cisplatin-based chemotherapy for testicular cancer results in temporary azoospermia in most men, with a recovery of spermatogenesis in about 50% of the patients after 2 years and 80% after 5 years. The germinal epithelium is very sensitive to radiation-induced damage, with changes to spermatogonia following as little as 0.2 Gy. Testicular doses of less than 0.2 Gy had no significant effect on FSH levels or sperm counts, whereas doses between 0.2 and 0.7 Gy caused a transient dose–dependent increase in FSH and reduction in sperm concentration, with a return to normal values within 12–24 months. No radiation dose threshold has been defined above which permanent azoospermia is inevitable; however, doses of 1.2 Gy and above are likely to be associated with a reduced risk of recovery of spermatogenesis; the time to recovery, if it is to occur, is also likely to be dose dependent.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J AndrolHome page
L. Marcon, B. F. Hales, and B. Robaire
Reversibility of the Effects of Subchronic Exposure to the Cancer Chemotherapeutics Bleomycin, Etoposide, and Cisplatin on Spermatogenesis, Fertility, and Progeny Outcome in the Male Rat
J Androl, July 1, 2008; 29(4): 408 - 417.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. A.E. van der Kaaij, N. Heutte, N. Le Stang, J. M.M. Raemaekers, A. H.M. Simons, P. Carde, E. M. Noordijk, C. Ferme, J. Thomas, H. Eghbali, et al.
Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol., July 1, 2007; 25(19): 2825 - 2832.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
F. Vaisheva, G. Delbes, B. F. Hales, and B. Robaire
Effects of the Chemotherapeutic Agents for Non-Hodgkin Lymphoma, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), on the Male Rat Reproductive System and Progeny Outcome
J Androl, July 1, 2007; 28(4): 578 - 587.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C. Wyns, M. Curaba, B. Martinez-Madrid, A. Van Langendonckt, W. Francois-Xavier, and J. Donnez
Spermatogonial survival after cryopreservation and short-term orthotopic immature human cryptorchid testicular tissue grafting to immunodeficient mice
Hum. Reprod., June 1, 2007; 22(6): 1603 - 1611.
[Abstract] [Full Text] [PDF]


Home page
J Bone Joint Surg BrHome page
T. N. Board, A. Karva, R. E. Board, A. K. Gambhir, and M. L. Porter
The prophylaxis and treatment of heterotopic ossification following lower limb arthroplasty
J Bone Joint Surg Br, April 1, 2007; 89-B(4): 434 - 440.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. A. Achille, Z. Rosberger, R. Robitaille, S. Lebel, J.-P. Gouin, B. D. Bultz, and P. T.K.Chan
Facilitators and obstacles to sperm banking in young men receiving gonadotoxic chemotherapy for cancer: the perspective of survivors and health care professionals
Hum. Reprod., December 1, 2006; 21(12): 3206 - 3216.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. J. Lee, L. R. Schover, A. H. Partridge, P. Patrizio, W. H. Wallace, K. Hagerty, L. N. Beck, L. V. Brennan, and K. Oktay
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
J. Clin. Oncol., June 20, 2006; 24(18): 2917 - 2931.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.